期刊文献+

心房颤动的抗凝治疗及进展 被引量:8

Updated anticoagulation therapy in atrial fibrillation
原文传递
导出
摘要 心房颤动的血栓栓塞防治的传统抗凝药物是华法林,近年来直接口服抗凝药物取得了重要进展,并且直接口服抗凝药物的研究中纳入了相当一部分合并瓣膜病变的患者。所有非瓣膜病房颤患者均应该基于血栓和出血风险给予抗凝治疗。多数患者直接口服抗凝药物的剂量相对固定,但是仍然需要考虑年龄、肾功能等因素采取适当的剂量。出血风险极高不能口服抗凝药物的患者可采用机械装置或手术治疗,但还需要更多研究证实。
作者 孙艺红
出处 《中华全科医师杂志》 2016年第10期740-743,共4页 Chinese Journal of General Practitioners
  • 相关文献

参考文献6

  • 1Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China[ J]. J Am Coil Cardiol, 2008,52(10) :865-868. DOI : 10. 1016/j. jacc. 2008.05. 042.
  • 2Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials [ J ]. Lancet, 2014,383 (9921) :955-962. DOI : 10. 1016/S0140- 6736( 13)62343-0.
  • 3Avezum A, Lopes RD, Schuhe PJ, et al. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation ( ARISTOTLE ) Trial [ J ]. Circulation, 2015, 132 (8): 624-632. DOI: 10. 1161/CIRCULATIONAHA. 114. 014807.
  • 4华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013,52(1):76-82. 被引量:597
  • 5Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin : the SAMe-TT2 R2 score [ J ]. Chest, 2013, 144(5 ) :1555-1563. DOI: 10. 137g/chest. 13-0054.
  • 6非瓣膜病心房颤动患者应用新型口服抗凝药物中国专家建议[J].中华心血管病杂志,2014,42(5):362-369. 被引量:79

二级参考文献18

  • 1Society of Cardiology, Chinese Medical Association.Retrospective investigation of hospitalized patients with atrial fibrillation in China's Mainland[J].Chinese Medical Journal,2004,17(12):1763-1767. 被引量:23
  • 2胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 3王小艳.急性冠脉综合征后6个月死亡和心肌梗死的预测:前瞻性的多国观察性研究(GRACE)[J].中国处方药,2006(11):25-26. 被引量:138
  • 4Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 5Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 6Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 7Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 8Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 9Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 10Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.

共引文献664

同被引文献41

引证文献8

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部